Transcriptomics enables researchers to study how the stable DNA ‘code’ of an organism is interpreted at a given moment in time.
Nanopore Technology for cDNA Research
A powerful technique for this is nanopore technology, which allows researchers to sequence millions of whole transcripts end-to-end in single reads. This gives them a powerful base to tackle challenges in the areas of full-length transcript identification, isoform characterization and quantification.
Oxford Nanopore's new '109' cDNA Sequencing Kits enable high-throughput sequencing of full-length cDNA, and can be run using as little as 1ng PolyA+ RNA.
These new kits allow the end-to-end sequencing of entire transcripts in single reads. This can be performed alongside accurate isoform-level transcriptome characterization experiments, as well as differential gene expression profiling, without compromising on cost, quantitation, computational or workflow complexity; the factors required to achieve this on other short or long read sequencing platforms.
As well as their 109 cDNA Sequencing Kits, Oxford Nanopore also offers a comprehensive guide to cDNA sequencing that contains all of the information necessary to get started.
Next-Generation cDNA Sequencing
The new cDNA kits can be used on all Oxford Nanopore devices, allowing users at any level and scale to generate very high yields of transcriptomic data for high-resolution novel isoform discovery, identification of low copy number transcripts and de novo sequencing of entire transcriptomes to high coverage.
For users of the MinION, yields of 10-15 million full-length transcripts per flow cell can be achieved, and on the PromethION this increases to more than 60 million.
About Oxford Nanopore Technologies
Oxford Nanopore Technologies Ltd has developed the world’s only real-time, long-read, direct DNA/RNA sequencing technology. Uniquely, it can be scaled from portable formats (MinION and Flongle) that can open up new decentralized models of biological analysis, to ultra-high-throughput devices (GridION and PromethION) that can address population-scale genomics and large genomes or projects.
Commercially available since 2015, the technology is in use globally, across myriad areas of scientific research. These include human genetics, cancer research, disease surveillance, environmental analysis, agriculture and most recently in food safety testing and health applications.
The Company’s goal is to enable the analysis of any living thing, by anyone, anywhere. For more information visit www.nanoporetech.com.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.